Using leftover patient samples for clinical research on blood diseases
Official title: The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research
Run by Invivoscribe, Inc. · NCT06222164 · Data updated 2026-11-12
This study is trying to use leftover blood and tissue samples from patients to help learn more about blood diseases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Invivoscribe, Inc. Industry-sponsored |
| Locations | 1 site (San Diego, California) |
| Status | Recruiting |
| Started | March 30, 2024 |
| Main results expected | March 30, 2027 |
| Study ends | June 30, 2027 |
| Registry record updated | May 4, 2025 |
| Trial ID | NCT06222164 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients aged 18 years and older whose specimens have been sent to LabPMM for clinical testing.
✕Probably not a fit
Patients whose samples have been obtained from third-party vendors or previously enrolled in clinical studies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on collecting residual human specimens and samples from patients whose samples have been sent for testing at LabPMM, LLC. The study aims to acquire various types of specimens, including peripheral blood, bone marrow, genomic DNA, and formalin-fixed paraffin-embedded tissue. These samples will be utilized for clinical research purposes either at LabPMM or partner institutions, contributing to the understanding of hematologic diseases.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and treatment of hematologic diseases by utilizing existing patient samples.
How similar studies have gone: Other studies utilizing residual specimens for research have shown promise, indicating that this approach is both valid and beneficial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing 2. Donor Age ≥ 18 years Exclusion Criteria: 1. Sample/specimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM 2. The specimens/samples have previously been enrolled in a clinical study
Where it's running
-
LabPMM
San Diego, California, United States Recruiting
Study contacts
- Study coordinator: Andrew Schut
- Email: aschut@invivoscribe.com
- Phone: +1 858.224.6600
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Romiplostim to help platelets grow after donor stem cell transplant
This phase II trial tests whether weekly romiplostim helps patients over 18 who receive a haploidentical or fully matched unrelated donor stem cell transplant to engraft platelets faster than best supportive care.
-
IL-5 CAR-T therapy for refractory or relapsed eosinophilic leukemia
We will test whether IL-5 CAR-T cells can help adults with CD125-positive refractory or relapsed eosinophilic leukemia.
-
Exploring immune defects in young patients with blood disorders
This study is trying to find out how immune system problems affect young people under 25 with blood disorders like autoimmune issues and bone marrow failure.
-
HLA mismatched stem cell transplantation for hematologic diseases
This study is testing if using stem cells from donors who aren't a perfect match can help people with blood cancers get the treatment they need when they can't find a suitable donor.
-
Go Wish Game to support advance care planning for adults with cancer or blood cancers
This project tries the Go Wish Game to help adults with refractory leukemia, lymphoma, multiple myeloma, or advanced solid tumors and their caregivers have end-of-life conversations and complete advance care planning.
-
Home blood transfusions for people with advanced blood cancers in hospice
The study will test whether offering home blood transfusions to adults with advanced or relapsed blood cancers who are eligible for hospice helps improve quality of life, mood, and end-of-life care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.